Abstract
In the study reported on by Papazian et al. (Sept. 16 issue),1 patients with the acute respiratory distress syndrome (ARDS) treated early with cisatracurium had improved 90-day survival and an increased number of ventilator-free days. We are concerned about a number of methodologic limitations that detract from the reliability of the findings. First, considering that patients who are not paralyzed can trigger the ventilator and paralyzed patients cannot, adequate blinding of study-group assignments among caregivers would seem to have been nearly impossible. Furthermore, patient−ventilator dyssynchrony was not formally monitored, nor were strategies to deal with it prespecified.2 Lacking that, it is conceivable that inadequate management of dyssynchrony in the placebo group could have predisposed to worse outcomes. Finally, the Medical Research Council (MRC) scale method used to evaluate muscle weakness was limited to 28 days (or to discharge from the intensive care unit [ICU]), a duration that may be too brief to recognize muscle weakness in patients who require prolonged mechanical ventilation, particularly if they are slow to awaken.3

This publication has 8 references indexed in Scilit: